Aptinyx to Participate in H.C. Wainwright BioConnect 2021 Conference – Watertown Public Opinion

Related Articles:

• Aptinyx to Launch Phase 2 Study of NYX-458 to Treat Cognitive Impairment May 20, 2019 Positive preclinical and Phase 1 clinical data support further assessmentof Aptinyx‘s investigational compound NYX-458 for the treatment of cognitive impairment associated with Parkinson’s disease in new Phase 2 studies. Aptinyx expects to launch a new Phase 2 clinical study in Parkinson’s patients this year, the company announced in a press release. “So far, 2019 has been marked by the achievement of…
• Aptinyx to Participate in H.C. Wainwright BioConnect 2021 Conference - Odessa American January 5, 2021 Aptinyx to Participate in H.C. Wainwright BioConnect 2021 Conference  Odessa American
• Aptinyx to Participate in H.C. Wainwright BioConnect 2021 Conference - Business Wire January 5, 2021 Aptinyx to Participate in H.C. Wainwright BioConnect 2021 Conference  Business Wire
• Monthly Research Review – December 2020 December 31, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
• Aptinyx’s Investigational Parkinson’s Therapy NYX-458 Enters Phase 1 Clinical Testing August 7, 2018 Aptinyx has launched a Phase 1 clinical trial of NYX-458, a potential treatment for cognitive impairment in Parkinson’s disease patients. The randomized, double-blind, placebo-controlled trial will be conducted in roughly 62 healthy volunteers to evaluate the safety, tolerability, and pharmacokinetics of the compound. Pharmacokinetics refers to a drug’s absorption, bioavailability, distribution, metabolism, and excretion in the body. Patients will receive both…
• Enrollment in Phase 2 Study of Cognitive Treatment Paused for Pandemic May 19, 2020 Aptinyx has paused patient enrollment in its Phase 2 trial evaluating NYX-458 to treat mild cognitive impairment in people with Parkinson’s disease due to the current COVID-19 pandemic.  The decision was made in light of the elevated risk this virus poses to an older patient population, and the challenges in assessing changes in cognitive skills remotely.  “In the midst of the…
• Oral Treatment in Phase 2 Trial, NYX-458, Seen to Aid Cognition in Primate Model Study February 5, 2020 Aptinyx‘s investigational oral compound NYX-458 was able to ease cognitive difficulties in a non-human primate model of Parkinson’s disease, including attention, working memory and executive thinking, a study reports. Its findings also suggest that NYX-458 — now in a Phase 2 clinical trial (NCT04148391) enrolling patients across the U.S. — does not interfere with levodopa treatment. The study, “NYX‐458 improves cognitive…
• Oral Treatment in Phase 2 Trial, NYX-458, Seen to Aid Cognition in Primate Model Study February 5, 2020 Aptinyx‘s investigational oral compound NYX-458 was able to ease cognitive difficulties in a non-human primate model of Parkinson’s disease, including attention, working memory and executive thinking, a study reports. Its findings also suggest that NYX-458 — now in a Phase 2 clinical trial (NCT04148391) enrolling patients across the U.S. — does not interfere with levodopa treatment. The study, “NYX‐458 improves cognitive…
• Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect Conference - GlobeNewswire January 6, 2021 Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect Conference  GlobeNewswire
• Phase 2 Study to Evaluate Possible Oral Treatment for Mild Cognitive Impairment in Parkinson’s December 9, 2019 Aptinyx will soon open a Phase 2 clinical study of NYX-458, a potential oral treatment of mild cognitive impairment (MCI) associated with Parkinson’s disease (PD). Although the main features of Parkinson’s involve difficulties with mobility and motor function, many patients also experience non-motor symptoms that include cognitive problems, for which few options exist. Parkinson’s is a progressive disease of the nervous system, but…
• Monthly Research Review: Jaunary 2020 January 31, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2020. The post is divided into seven parts based on the type of research: Basic biology, Disease mechanism, Clinical research, New clinical trials, Clinical trial news, Other news, and…
• Annovis Bio to Present at H.C. Wainwright BioConnect 2021 Conference - Yahoo Finance January 5, 2021 Annovis Bio to Present at H.C. Wainwright BioConnect 2021 Conference  Yahoo Finance
• Intec Pharma to Participate in the HC Wainwright Global Life Sciences Conference - PRNewswire April 1, 2019 Intec Pharma to Participate in the HC Wainwright Global Life Sciences Conference  PRNewswireJERUSALEM, April 1, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will ...
• Intec Pharma to Participate in the HC Wainwright Global Life Sciences Conference - BioSpace April 1, 2019 Intec Pharma to Participate in the HC Wainwright Global Life Sciences Conference  BioSpacePublished: Apr 01, 2019. JERUSALEM, April 1, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that ...
• 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
• Genentech's Risdiplam Meets Primary Endpoint in Pivotal SUNFISH Trial in People With Type 2 or 3 Spinal Muscular Atrophy - Watertown Public Opinion November 11, 2019 Genentech's Risdiplam Meets Primary Endpoint in Pivotal SUNFISH Trial in People With Type 2 or 3 Spinal Muscular Atrophy  Watertown Public Opinion
• Aptinyx to Present Preclinical Data on NYX-458 at the AD/PD 14th International Conference on Alzheimer's & Parkinson's Diseases - GlobeNewswire March 22, 2019 Aptinyx to Present Preclinical Data on NYX-458 at the AD/PD 14th International Conference on Alzheimer's & Parkinson's Diseases  GlobeNewswireEVANSTON, Ill., March 22, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative ...
• Aptinyx to Present Preclinical Data on NYX-458 at the AD/PD 14th International Conference on Alzheimer's & Parkinson's Diseases - Nasdaq March 22, 2019 Aptinyx to Present Preclinical Data on NYX-458 at the AD/PD 14th International Conference on Alzheimer's & Parkinson's Diseases  NasdaqEVANSTON, Ill., March 22, 2019-- Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of.
• Anavex Life Sciences to Present at the HC Wainwright Annual Global Life Sciences Conference - Nasdaq April 5, 2019 Anavex Life Sciences to Present at the HC Wainwright Annual Global Life Sciences Conference  NasdaqNEW YORK, April 05, 2019-- Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the.
• Anavex Life Sciences to Present at the H.C. Wainwright Annual Global Life Sciences Conference - GlobeNewswire April 5, 2019 Anavex Life Sciences to Present at the H.C. Wainwright Annual Global Life Sciences Conference  GlobeNewswireNEW YORK, April 05, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage ...
• ProMIS Neurosciences to Present at HC Wainwright Investment Conference - P&T Community September 3, 2019 ProMIS Neurosciences to Present at HC Wainwright Investment Conference  P&T CommunityCompany to showcase its innovative Alzheimer's, Parkinson's and ALS programs. TORONTO and CAMBRIDGE, MA, Sept. 3, 2019 /PRNewswire/ - ProMIS ...
• ProMIS Neurosciences to Present at H.C. Wainwright Investor Conference - GlobeNewswire September 3, 2019 ProMIS Neurosciences to Present at H.C. Wainwright Investor Conference  GlobeNewswireCompany to showcase its innovative Alzheimer's, Parkinson's and ALS programs.